UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 非プラチナ製剤ベースの癌化学療法の神経学的合併症の概要 overview of neurologic complications of non platinum cancer chemotherapy
2. 女性の転移性乳癌に対する全身療法：化学療法 systemic treatment of metastatic breast cancer in women chemotherapy
3. 転移性軟部組織肉腫の全身治療 systemic treatment of metastatic soft tissue sarcoma
4. アントラサイクリン系以外の癌化学療法剤の心毒性 cardiotoxicity of nonanthracycline cancer chemotherapy agents
5. 化学療法関連腎毒性および腎不全患者における用量調整 chemotherapy related nephrotoxicity and dose modification in patients with renal insufficiency

English Journal

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.

Yoshida T1, Ozawa Y1, Kimura T2, Sato Y2, Kuznetsov G3, Xu S3, Uesugi M2, Agoulnik S3, Taylor N3, Funahashi Y3, Matsui J1.
British journal of cancer.Br J Cancer.2014 Mar 18;110(6):1497-505. doi: 10.1038/bjc.2014.80. Epub 2014 Feb 25.
BACKGROUND: Eribulin mesilate (eribulin), a non-taxane microtubule dynamics inhibitor, has shown trends towards greater overall survival (OS) compared with progression-free survival in late-stage metastatic breast cancer patients in the clinic. This finding suggests that eribulin may have additional
PMID 24569463

Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy.

Wozniak KM1, Wu Y, Farah MH, Littlefield BA, Nomoto K, Slusher BS.
Neurotoxicity research.Neurotox Res.2013 Oct;24(3):338-44. doi: 10.1007/s12640-013-9394-3. Epub 2013 Apr 30.
Eribulin mesylate (E7389, INN:eribulin mesilate Halaven(®)) is a non-taxane microtubule dynamics inhibitor currently in clinical use for advanced breast cancer. Other microtubule-targeting agents for breast cancer, including paclitaxel and ixabepilone, display a common treatment dose-limiting toxic
PMID 23637052

Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.

van Hasselt JG1, Gupta A, Hussein Z, Beijnen JH, Schellens JH, Huitema AD.
British journal of clinical pharmacology.Br J Clin Pharmacol.2013 Sep;76(3):412-24. doi: 10.1111/bcp.12143.
AIMS: Eribulin mesilate is an inhibitor of microtubule dynamics that is approved for the treatment of late-stage metastatic breast cancer. Neutropenia is one of the major dose-limiting adverse effects of eribulin. The objective of this analysis was to develop a population pharmacokinetic-pharmacodyn
PMID 23601153

リンク元	「エリブリン」
関連記事	「mesilate」